{"id":"W3168407158","doi":"10.1200/jco.2021.39.15_suppl.8006","title":"Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"Pfizer","keywords":"Medicine; Cytokine release syndrome; Common Terminology Criteria for Adverse Events; Adverse effect; Neutropenia; Internal medicine; Multiple myeloma; Gastroenterology; Anemia; Toxicity; Chimeric antigen receptor; Oncology; Immunology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007340281,0.0003882317,0.000682511,0.000257139,0.0001956305,0.0003935827,0.0002359047,0.000400251,0.001128549],"category_scores_gemma":[0.0005174672,0.0001947251,0.0006091903,0.0002644488,0.0003355486,0.0003778278,0.0001914813,0.001109079,0.0003639873],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006260701,"about_ca_system_score_gemma":0.0003770694,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004280028,"about_ca_topic_score_gemma":0.0005480991,"domain_scores_codex":[0.9997501,0.00008835004,0.00001852723,0.00005210784,0.00005253801,0.00003848114],"domain_scores_gemma":[0.9997591,0.00005196078,0.00008404904,0.00002058675,0.00001467063,0.0000696512],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3036545,0.01602715,0.09290612,0.0009655376,0.001301969,0.0007597413,0.0005277899,0.005073483,0.1212527,0.0002219015,0.002560464,0.4547485],"study_design_scores_gemma":[0.06826403,0.5786923,0.3063849,0.00009203931,0.001739814,0.003033497,0.00009226544,0.004414581,0.02704804,0.000329304,0.009854856,0.00005447628],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947832,0.003707555,0.0002568312,0.0001237352,0.00001727194,0.0001084821,0.0002115245,0.00003468525,0.0007567171],"genre_scores_gemma":[0.9981776,0.0006726889,0.0002011645,0.0001158509,0.00003473828,0.0000520861,0.0003597234,0.000004460149,0.0003815643],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001128549,"threshold_uncertainty_score":0.00454247,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06914840343259031,"score_gpt":0.4273267521688274,"score_spread":0.3581783487362371,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}